BioCentury | Jan 16, 2021
Product Development

Arcus’ CD73 inhibitor challenges AZ’s oleclumab, at least six others follow in oncology: Data Byte

...compounds in Phase I testing for COVID-19. Selina Koch [MERGED] AstraZeneca plc I-Mab Biopharma Surface Oncology Inc. Novartis AG Corvus Pharmaceuticals Inc. Tracon Pharmaceuticals Inc. Eli...
BioCentury | Dec 22, 2020
Regulation

Dec. 21-23 Regulatory Quick Takes: positive CHMP opinion for Pfizer-BioNTech COVID-19 vaccine; plus Urovant’s approval, a Feb. 9 adcomm for Keytruda in TNBC, NMPA reviewing a subcutaneous PD-L1, and more

...subcutaneous anti-PD-1/PD-L1 antibody globally. Simcere holds commercialization rights to envafolimab in China for cancer while Tracon Pharmaceuticals Inc....
BioCentury | Dec 24, 2019
Company News

Dec. 23 Company Quick Takes: Theravance partners with Pfizer; plus Fortress-AZ, Progenics, Tracon-Alphamab Oncology-3D Medicines

...of 85% to 87% with three independent evaluators. Progenics stock rose $0.50 (10%) to $5.67. Tracon...
...3D Medicines partner for PD-L1 antibody Alphamab Oncology Ltd. (HKEX:9966) and 3D Medicines Corp. granted Tracon Pharmaceuticals Inc....
...NASDAQ:TCON) development and commercialization rights in North America to envafolimab (KN035) for soft tissue sarcoma. Tracon...
BioCentury | Aug 21, 2019
Company News

Management tracks: VenatoRx builds out development team; plus Arbutus, Cadent and Arsenal Capital

...Malvern. Pa.) hired Jennifer Ellis as SVP, quality. She was head of quality assurance at Tracon Pharmaceuticals Inc....
BioCentury | Aug 2, 2019
Clinical News

Aug. 2 Clinical Quick Takes: AB Sciences halts metastatic melanoma program; plus NIH, Adaptimmune and more

...Tracon dose first solid tumor patient with anti-CD73 mAb I-Mab Biopharma (Shanghai, China) and partner Tracon Pharmaceuticals Inc....
...in a U.S. Phase I trial of anti-CD73 mAb TJD5 in solid tumors. I-Mab and Tracon...
...A4 TCR, MAGE-A4 SPEAR T-cell therapy, MAGEA4 TCR Masiviera, masitinib (AB1010, masican, masipro) TJD5 AB Science S.A. I-Mab Biopharma Kiyatec Inc. Tracon Pharmaceuticals Inc. National...
BioCentury | Jun 21, 2019
Finance

VC pair seeds cancer play Yukin, seeks preclinical readout

...but she declined to disclosed any specific indications or timelines related to the company's research. Tracon...
...implications in hematologic malignancies, but said the company had no further comment on the former Tracon...
BioCentury | Apr 19, 2019
Clinical News

Tracon discontinues CD105 mAb carotuximab

...interim futility analysis of the Phase III TAPPAS trial to treat advanced or metastatic angiosarcoma. Tracon Pharmaceuticals Inc....
...alone. Carotuximab is a human chimeric mAb against endoglin (CD105; ENG). Brian Moy, Assistant Editor Carotuximab (IV TRC105) Tracon Pharmaceuticals Inc. Endoglin...
BioCentury | Jan 5, 2019
Finance

Ready to launch

...NEEQ:430187) Vocimagene amiretrorepvec/extended release flucytosine (Toca 511/Toca FC) High-grade glioma Phase III interim data 1H19 Tracon Pharmaceuticals Inc....
BioCentury | Jan 4, 2019
Clinical News

Tracon's carotuximab fails Phase II for RCC

...that trial is in September 2019. An interim analysis of TAPPAS is expected this quarter. Tracon Pharmaceuticals Inc....
...Progression-free survival (PFS); overall response rate (ORR) Status: Phase II data Milestone: NA Brian Moy Carotuximab (IV TRC105) Tracon Pharmaceuticals Inc. Endoglin...
BioCentury | Oct 4, 2018
Company News

Management tracks: Grail, Nimbus

...sector, joined the firm in 2008. He is a director at Allakos Inc. (NASDAQ:ALLK) and Tracon Pharmaceuticals Inc....
Items per page:
1 - 10 of 79
BioCentury | Jan 16, 2021
Product Development

Arcus’ CD73 inhibitor challenges AZ’s oleclumab, at least six others follow in oncology: Data Byte

...compounds in Phase I testing for COVID-19. Selina Koch [MERGED] AstraZeneca plc I-Mab Biopharma Surface Oncology Inc. Novartis AG Corvus Pharmaceuticals Inc. Tracon Pharmaceuticals Inc. Eli...
BioCentury | Dec 22, 2020
Regulation

Dec. 21-23 Regulatory Quick Takes: positive CHMP opinion for Pfizer-BioNTech COVID-19 vaccine; plus Urovant’s approval, a Feb. 9 adcomm for Keytruda in TNBC, NMPA reviewing a subcutaneous PD-L1, and more

...subcutaneous anti-PD-1/PD-L1 antibody globally. Simcere holds commercialization rights to envafolimab in China for cancer while Tracon Pharmaceuticals Inc....
BioCentury | Dec 24, 2019
Company News

Dec. 23 Company Quick Takes: Theravance partners with Pfizer; plus Fortress-AZ, Progenics, Tracon-Alphamab Oncology-3D Medicines

...of 85% to 87% with three independent evaluators. Progenics stock rose $0.50 (10%) to $5.67. Tracon...
...3D Medicines partner for PD-L1 antibody Alphamab Oncology Ltd. (HKEX:9966) and 3D Medicines Corp. granted Tracon Pharmaceuticals Inc....
...NASDAQ:TCON) development and commercialization rights in North America to envafolimab (KN035) for soft tissue sarcoma. Tracon...
BioCentury | Aug 21, 2019
Company News

Management tracks: VenatoRx builds out development team; plus Arbutus, Cadent and Arsenal Capital

...Malvern. Pa.) hired Jennifer Ellis as SVP, quality. She was head of quality assurance at Tracon Pharmaceuticals Inc....
BioCentury | Aug 2, 2019
Clinical News

Aug. 2 Clinical Quick Takes: AB Sciences halts metastatic melanoma program; plus NIH, Adaptimmune and more

...Tracon dose first solid tumor patient with anti-CD73 mAb I-Mab Biopharma (Shanghai, China) and partner Tracon Pharmaceuticals Inc....
...in a U.S. Phase I trial of anti-CD73 mAb TJD5 in solid tumors. I-Mab and Tracon...
...A4 TCR, MAGE-A4 SPEAR T-cell therapy, MAGEA4 TCR Masiviera, masitinib (AB1010, masican, masipro) TJD5 AB Science S.A. I-Mab Biopharma Kiyatec Inc. Tracon Pharmaceuticals Inc. National...
BioCentury | Jun 21, 2019
Finance

VC pair seeds cancer play Yukin, seeks preclinical readout

...but she declined to disclosed any specific indications or timelines related to the company's research. Tracon...
...implications in hematologic malignancies, but said the company had no further comment on the former Tracon...
BioCentury | Apr 19, 2019
Clinical News

Tracon discontinues CD105 mAb carotuximab

...interim futility analysis of the Phase III TAPPAS trial to treat advanced or metastatic angiosarcoma. Tracon Pharmaceuticals Inc....
...alone. Carotuximab is a human chimeric mAb against endoglin (CD105; ENG). Brian Moy, Assistant Editor Carotuximab (IV TRC105) Tracon Pharmaceuticals Inc. Endoglin...
BioCentury | Jan 5, 2019
Finance

Ready to launch

...NEEQ:430187) Vocimagene amiretrorepvec/extended release flucytosine (Toca 511/Toca FC) High-grade glioma Phase III interim data 1H19 Tracon Pharmaceuticals Inc....
BioCentury | Jan 4, 2019
Clinical News

Tracon's carotuximab fails Phase II for RCC

...that trial is in September 2019. An interim analysis of TAPPAS is expected this quarter. Tracon Pharmaceuticals Inc....
...Progression-free survival (PFS); overall response rate (ORR) Status: Phase II data Milestone: NA Brian Moy Carotuximab (IV TRC105) Tracon Pharmaceuticals Inc. Endoglin...
BioCentury | Oct 4, 2018
Company News

Management tracks: Grail, Nimbus

...sector, joined the firm in 2008. He is a director at Allakos Inc. (NASDAQ:ALLK) and Tracon Pharmaceuticals Inc....
Items per page:
1 - 10 of 79